US2010221209A1PendingUtilityA1

Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses

78
Assignee: UNIV SOUTHERN CALIFORNIAPriority: Nov 5, 1997Filed: Oct 29, 2009Published: Sep 2, 2010
Est. expiryNov 5, 2017(expired)· nominal 20-yr term from priority
Inventors:David A. Horwitz
A61K 40/416A61K 40/22A61K 40/11C12N 5/0636C12N 2501/599C12N 2501/15C12N 2501/23
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Claims

exact text as granted — not AI-modified
2 . A method for treating an autoimmune disorder in a patient comprising:
 a) removing peripheral blood mononuclear cells (PBMC) from said patient;   b) treating said cells with a regulatory composition to generate regulatory T cells, said regulatory composition comprising anti-CD2 and anti-CD3; and;   c) reintroducing said regulatory T cells to said patient to suppress an aberrant immune response.   
   
   
       3 . A method for treating an autoimmune disorder in a patient comprising:
 a) removing peripheral blood mononuclear cells (PBMC) from said patient;   b) treating said cells with a regulatory composition to induce said cells to produce immunosuppressive levels of TGF-β; said regulatory composition comprising anti-CD2 and anti-CD3; and;   c) reintroducing said cells to said patient to suppress aberrant immune responses.   
   
   
       4 . A method according to claim  1  or  2 , said regulatory composition further comprising TGF-β. 
   
   
       5 . A method according to claim  1  or  2 , said regulatory composition further comprising II-2. 
   
   
       6 . A method according to claim  1  or  2 , said regulatory composition further comprising TGF-β and IL-2. 
   
   
       7 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+. 
   
   
       8 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and said regulatory composition further comprises TGF-β. 
   
   
       9 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and said regulatory composition further comprises IL-2. 
   
   
       10 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and said regulatory composition further comprises TGF-β and IL-2. 
   
   
       11 . A method according to claim  1  or  2 , wherein said PBMC comprise CD4+. 
   
   
       12 . A method according to claim  1  or  2 , wherein said PBMC comprise CD4+ and said regulatory composition further comprises TGF-13. 
   
   
       13 . A method according to claim  1  or  2 , wherein said PBMC comprise CD4+ and said regulatory composition further comprises IL-2. 
   
   
       14 . A method according to claim  1  or  2 , wherein said PBMC comprise CD4+ and said regulatory composition further comprises TGF-β and IL-2. 
   
   
       15 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and CD4+. 
   
   
       16 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises TGF-6. 
   
   
       17 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises IL-2. 
   
   
       18 . A method according to claim  1  or  2 , wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises TGF-β and IL-2. 
   
   
       19 . A method according to claim  1  or  2 , wherein said PBMC comprise NK T cells. 
   
   
       20 . A method according to claim  1  or  2 , wherein said PBMC comprise NK T cells and said regulatory composition further comprises TGF-β. 
   
   
       21 . A method according to claim  1  or  2 , wherein said PBMC comprise NK T cells and said regulatory composition further comprises IL-2. 
   
   
       22 . A method according to claim  1  or  2 , wherein said PBMC comprise NK T cells and said regulatory composition further comprises TGF-β and IL-2. 
   
   
       23 . A method according to claim  1  or  2 , wherein said aberrant immune response is a cell-mediated autoimmune disease selected from the group consisting of Hashimoto's disease, polymyositis, disease inflammatory bowel disease, multiple sclerosis, diabetes mellitus, rheumatoid arthritis, and scleroderma. 
   
   
       24 . A method according to  claim 2  wherein said wherein said aberrant immune response is an antibody mediated disease selected from the group consisting of pemphigus vulgaris, myasthenia gravis, hemolytic anemia, thrombocytopenia purpura, Grave's disease, dermatomyositis and Sjogren's disease.

Join the waitlist — get patent alerts

Track US2010221209A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.